Standard BioTools (LAB) Aandeel Koers
Standard BioTools Koers
De omzet is de afgelopen 19 jaar met 14,6% per jaar gegroeid tot 85,33 Miljoen USD. De nettowinstmarge van Standard BioTools ligt op -87,8% en is ten opzichte van -45,4% enkele jaren eerder gedaald. Analisten hanteren een mediaan koersdoel van 1,58 USD — dat impliceert 139,5% boven de huidige koers. Van de 7 analisten geven 4 het aandeel een koopadvies — per saldo een Kopen-consensus.
Standard BioTools aandeelkoers
Standard BioTools bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Standard BioTools
The business model of Fluidigm Corp focuses on providing innovative technologies for large-scale biological research. The company develops and sells microfluidic systems, instruments, consumables, and software solutions that enable scientists to analyze biological systems at the cellular level. Fluidigm Corp's platforms are designed to enhance workflows and deliver high-quality data for a wide range of applications, including genomics, proteomics, and single-cell analysis. By offering comprehensive and advanced solutions, Fluidigm Corp aims to empower researchers in their quest for new discoveries and deeper understanding of biological processes.
Fluidigm Corp is primarily active in the life sciences industry.
The main competitors of Fluidigm Corp in the market include companies such as Illumina, Thermo Fisher Scientific, and Agilent Technologies.
Fluidigm Corp is a renowned biotechnology company that specializes in the development and commercialization of innovative tools for life sciences research. Founded in 1999, Fluidigm Corp has consistently addressed critical challenges in various fields including genomics, proteomics, and single-cell analysis. The company's cutting-edge microfluidic technologies enable researchers to gain insights into biological systems with higher precision, efficiency, and cost-effectiveness. With a commitment to advancements in medical diagnostics, drug discovery, and personalized medicine, Fluidigm Corp continues to revolutionize the way researchers analyze and understand complex biological processes.
Fluidigm Corp has achieved significant milestones throughout its history. Some key accomplishments include the development and commercialization of innovative microfluidic solutions for life sciences research and clinical diagnostics. The company's revolutionary biomarker detection technology, CyTOF®, has gained widespread recognition for its ability to provide high-resolution single-cell analysis. Additionally, Fluidigm Corp has expanded its product portfolio by introducing high-throughput genotyping and gene expression systems, empowering researchers to unlock valuable insights into complex biological processes. The company's dedication to scientific excellence and ongoing innovation has helped establish Fluidigm Corp as a pioneering force in the field of microfluidics and life sciences.
Fluidigm Corp is primarily present in countries and regions across the globe. With a strong international presence, the company operates in key markets such as North America, Europe, Asia Pacific, and Latin America. Fluidigm Corp's cutting-edge technologies and innovative solutions have gained recognition and adoption worldwide, allowing it to serve customers and partners in various industries and research fields. From its headquarters in South San Francisco, California, Fluidigm Corp has expanded its reach, establishing offices, collaborations, and customer relationships in numerous countries and regions, solidifying its position as a global leader in pioneering microfluidic technologies and scientific advancements.
Fluidigm Corp represents a set of values and corporate philosophy centered around innovation, collaboration, and scientific advancement. With a focus on developing and commercializing transformative technologies, Fluidigm Corp strives to empower researchers and clinicians to make groundbreaking discoveries. The company's dedication to precision and accuracy in their microfluidic systems is evident in their commitment to providing customers with high-quality tools for genomic research, single-cell analysis, and mass cytometry. With a customer-centric approach, Fluidigm Corp aims to drive advancements in the fields of life sciences and healthcare by enabling deeper insights and accelerating discoveries.
Analisten hanteren momenteel een gemiddeld koersdoel van 1,58 USD voor het aandeel Standard BioTools (mediaan: 1,58 USD), oftewel +139,5 % ten opzichte van de laatste koers. De consensus is gebaseerd op 7 analistenratings.
6 analisten beoordelen het aandeel Standard BioTools momenteel: 4 adviseren kopen, 2 houden en 0 verkopen. Voor 2026 verwachten analisten dat Standard BioTools een omzet van 82,50 Miljoen USD en winst per aandeel van -0,10 USD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel Standard BioTools op 0,59 EUR (0,66 USD).
Het aandeel Standard BioTools (LAB) is genoteerd aan 5 beurzen, waaronder: NASDAQ (FLDM), SIX (Zürich) (FLB.SW), Frankfurt (FLB.F), München (FLB.MU), Düsseldorf (FLB.DU).
Fluidigm is a biotechnology company that develops innovative technology platforms and products for the analysis of single cells, genomics, and proteomics. The company was founded in 1999 and is headquartered in San Francisco, California. Fluidigm offers products and solutions for the study of single cells and cellular processes. The technology platforms include single-cell genomics, single-cell proteomics, and microfluidic systems. These platforms allow researchers to analyze and investigate individual cells. Fluidigm has a wide range of products that can be grouped into three main categories: gene expression, genotyping, and proteomics. Gene expression products are specifically designed for the analysis of single cells, including the C1 system and Biomark HD technology. The Biomark HD system is Fluidigm's flagship product and is used by researchers worldwide for comprehensive analysis of gene expression profiles. Fluidigm's genotyping product line is primarily used in the pharmaceutical industry and includes assays and chips that enable scientists to study individual genes in the human body. The assays are delivered by the EP1 platform, which performs highly precise genotyping processes and saves resources and time. Fluidigm's proteomics platform allows researchers to analyze proteins and proteome chains in single cells. The company offers a wide range of products, including chips, assays, and kits that detect the identity and concentration of proteins based on mass spectrometry. Fluidigm distributes its products worldwide and serves a broad customer base, including leading pharmaceutical and biotech companies, academic institutions, government agencies, and research laboratories. Fluidigm's business model is based on two core strategies, namely technology innovation and market penetration. The company continuously invests in research and development to remain at the forefront of its technology areas. This has resulted in a broad patent portfolio and a growing customer base. Fluidigm's market penetration strategy focuses on selling products to a variety of customers, including academic institutions, government agencies, and companies. The company has built a distribution infrastructure to sell its products worldwide and provide excellent customer support. In summary, Fluidigm is a biotechnology company that develops and sells innovative technology platforms and products for the analysis of single cells, genomics, and proteomics. The business model is based on technology innovation and market penetration strategy to sell its products worldwide and expand its customer base.
De verwachte omzet van Standard BioTools bedraagt 82,50 Miljoen USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van Standard BioTools bedraagt -38,46 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Standard BioTools bedraagt momenteel -6,61. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Standard BioTools-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Standard BioTools bedraagt momenteel 3,08. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Standard BioTools-aandeel.
De Eulerpool Kwaliteitsscore voor Standard BioTools is 2/10.
De ISIN van Standard BioTools is US34385P1084. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Standard BioTools is A0RADJ. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Standard BioTools is LAB. Onder dit beurstickersymbool wordt het Standard BioTools-aandeel op de beurs verhandeld.
Standard BioTools aandeel
Standard BioTools Peer Group
Standard BioTools Ticker
Standard BioTools FIGI
Alle fundamentals en diepgaande analyse van Standard BioTools
Onze aandelenanalyse van het Standard BioTools-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Standard BioTools. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: